Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Consensus Target Price from Analysts
Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...
Fintel on MSN8d
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation
Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...
Immunic (IMUX) Has a New Rating from William Blair
Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...
Companies Like Immunic (NASDAQ:IMUX) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Yahoo Finance2d
Immunic, Inc. (IMUX)
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...
Nasdaq15d
William Blair Initiates Coverage of Immunic (IMUX) with Outperform Recommendation
The firm increased its portfolio allocation in IMUX by 12.46% over the last quarter. Soleus Capital Management holds 7,293K shares representing 8.10% ownership of the company. No change in the ...